In conclusion, we identified that anti-CCP2 titers constitute an independent factor associated not only with the presence but also with the severity of RA-ILD; the relevance of these markers in patients with established ILD for future outcomes, such as progression of lung involvement and mortality, remains to be established. This evidence concerns the gene AGBL2 and interstitial lung disease.